ProQR Therapeutics N.V.

Last updated September 27, 2026

Organization details

Legal name
ProQR Therapeutics N.V.
Ownership
Public
Status
Active
Headquarters country
Netherlands
Ticker symbol
PRQR
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001612940

Board of directors

Chief executives

Boer Daniel Anton De · Chief Executive Officer
Since March 2026

Board connections

3 of this board's directors also sit on 6 other boards.

Network of ProQR Therapeutics N.V.'s board connections BioCryst Pharmaceuticals Inc. BioCryst Pharmaceutica... Dianthus Therapeutics Inc. Dianthus Therapeutics... MannKind Corporation MannKind Corporation Spyre Therapeutics Inc. Spyre Therapeutics Inc... X4 Pharmaceuticals Inc. X4 Pharmaceuticals Inc... Xilio Therapeutics Inc. Xilio Therapeutics Inc... Alison Frances Lawton Alison Frances Lawto... James Samuel Shannon James Samuel Shannon Theresa Heggie Theresa Heggie ProQR Therapeutics N.V.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$1,342,385
5 purchases by 2 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jul 31, 2026 Boer Daniel Anton De Director, Officer (Chief Executive Officer) Open-market purchase +200,000 $1.77 $353,960
Jul 17, 2026 Bart Filius Director Open-market purchase +150,000 $1.72 $257,925
Jul 9, 2026 Boer Daniel Anton De Director, Officer (Chief Executive Officer) Open-market purchase +150,000 $1.74 $261,000
Jul 7, 2026 Boer Daniel Anton De Director, Officer (Chief Executive Officer) Open-market purchase +150,000 $1.59 $238,500
Jun 26, 2026 Bart Filius Director Open-market purchase +150,000 $1.54 $231,000

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.